Dopamine receptors in striatum are important for healthy brain functioning and are the target of levodopa-based therapy in Parkinson's disease. Lateralization of dopaminergic neurotransmission in striata from different hemispheres occurs in patients, but also in healthy individuals. Our data show that the affinity of dopamine binding to dopamine D1 receptors is significantly higher in left than in right striatum. Analysis of data from radioligand binding to striatal samples from naïve, 6-hydroxydopamine lesioned, levodopa-treated and levodopa-induced dyskinetic rats shows differential receptor structure and gives hints on the causes of right/left lateralization of dopamine binding to striatal D1 receptors. Moreover, binding data showed loss of lateralization in levodopa (L-DOPA)-induced dyskinetic rats.

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Instituto de Salud Carlos 3 Valderrebollo 5 28031 Madrid Spain

Institute of Physiology Academy of Sciences Videnska 1083 14220 Prague Czech Republic

Laboratory of Neuroanatomy and Experimental Neurology Center for Research in Molecular Medicine and Chronic Diseases University of Santiago de Compostela 15782 Santiago de Compostela Spain

Laboratory of Neuroanatomy of Basal Ganglia Neurosciences Division Center for Applied Medical Research University of Navarra 31008 Pamplona Spain

Molecular Neurobiology Laboratory Department of Biochemistry and Molecular Biology Faculty of Biology University of Barcelona 08028 Barcelona Spain

School of Pharmacy and Biomedical Sciences University of Central Lancashire PR1 2HE Preston UK

Zobrazit více v PubMed

Pharmacol Ther. 2007 Dec;116(3):343-54 PubMed

J Biol Chem. 2004 Aug 20;279(34):35671-8 PubMed

FASEB J. 2011 Oct;25(10):3465-76 PubMed

Mov Disord. 1998 Sep;13(5):788-97 PubMed

Neuroreport. 2014 Oct 22;25(15):1191-7 PubMed

J Neurosci. 2001 Aug 15;21(16):6252-63 PubMed

Neuropsychobiology. 2001;43(3):192-9 PubMed

Neuropharmacology. 2015 Oct;97:365-75 PubMed

J Biol Chem. 2003 May 30;278(22):20196-202 PubMed

Brain. 2009 May;132(Pt 5):1366-75 PubMed

J Mol Signal. 2013 Dec 05;8(1):13 PubMed

Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8606-11 PubMed

Mol Pharmacol. 2013 Aug;84(2):190-200 PubMed

PLoS One. 2011 Jan 11;6(1):e16088 PubMed

Neuropharmacology. 2014 Apr;79:688-706 PubMed

Eur J Neurosci. 1998 Aug;10(8):2694-706 PubMed

Mol Pharmacol. 2005 Feb;67(2):460-9 PubMed

Nucl Med Commun. 1998 Aug;19(8):781-7 PubMed

Synapse. 1988;2(5):546-57 PubMed

Arch Gen Psychiatry. 2003 Mar;60(3):311-9 PubMed

J Biol Chem. 2007 Oct 12;282(41):30062-9 PubMed

Biochem Pharmacol. 2009 Dec 15;78(12):1456-63 PubMed

Eur J Neurosci. 2011 May;33(9):1706-15 PubMed

J Neurosci Res. 1990 Aug;26(4):461-73 PubMed

Life Sci. 1982 Jun 21;30(25):2155-62 PubMed

Int J Mol Sci. 2014 May 14;15(5):8570-90 PubMed

Brain Res. 1988 Jul 5;455(1):43-8 PubMed

Cell. 2002 Oct 18;111(2):219-30 PubMed

Mol Pharmacol. 2006 Jun;69(6):1905-12 PubMed

Brain Res Mol Brain Res. 2001 Mar 5;87(2):271-9 PubMed

Prog Mol Biol Transl Sci. 2010;91:41-52 PubMed

Eur J Pharmacol. 2001 Sep 21;427(3):187-93 PubMed

Brain Res. 1982 Feb 18;234(1):53-63 PubMed

Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):654-9 PubMed

Front Psychol. 2013 Dec 11;4:939 PubMed

Eur Neuropsychopharmacol. 2015 Sep;25(9):1470-9 PubMed

Anat Embryol (Berl). 1994 Aug;190(2):181-94 PubMed

Biol Psychol. 2008 Jan;77(1):98-101 PubMed

Mol Neurobiol. 2015 Dec;52(3):1408-1420 PubMed

J Neurosci Methods. 2005 Feb 15;141(2):251-60 PubMed

J Biol Chem. 2010 Aug 27;285(35):27346-59 PubMed

Neuropsychopharmacology. 2009 Apr;34(5):1277-87 PubMed

Neuropharmacology. 2007 Mar;52(3):1003-14 PubMed

PLoS One. 2013 Sep 06;8(9):e74512 PubMed

J Neurochem. 2001 Sep;78(5):981-90 PubMed

Neuron. 2008 May 22;58(4):557-70 PubMed

Exp Neurobiol. 2015 Mar;24(1):90-4 PubMed

J Cogn Neurosci. 2014 May;26(5):1039-48 PubMed

Nat Chem Biol. 2009 Mar;5(3):131-4 PubMed